Bullish Case: Greenlight Capital's largest disclosed long is ACHC at ~$29.9, a quality behavioral-health compounder down 51.8% over five years; call volume ran 99% above puts this week, and Helium's term-structure trace shows near-dated upside IV (89.8% at Nov 21) far exceeding downside (~43%), signaling concentrated bullish convexity demand. Any DOJ/insurance resolution or occupancy beat could drive a fast mean-reversion re-rate toward the low-to-mid $30s.

Bearish Case: The AI price forecast is -3.05% with a weak -0.1 realized correlation, and the term structure is backwardated with near-term market IV at 66.4% — the market is paying up for imminent downside. Helium's downside PDF mass at $30 (0.284) mirrors market-implied weight, deep OTM puts carry 160-200% IV, and five-year drawdown history plus regulatory overhang argue a breakout fails and price retests $27-28.

Potential Outcomes:

1. Range $27-32 into Q4 earnings (Feb 2027) — 40%: backwardated IV (66%→56%) decays if no news; falsified by a close outside the band.
2. Upside grind to $33-35 — 25%: call-heavy flow (99% more calls) and Helium's high Nov upside-IV trace support convexity; falsified by repeated $31.4 rejects.
3. Drop to $25-27 — 20%: -3.05% AI forecast + -0.1 correlation favor downside; falsified by reclaiming $32 on volume.
4. Vol shock >±15% — 10%: regulatory/DOJ headline; falsified by IV collapsing below 50% into Nov 21.
5. M&A/strategic bid — 5%: deep 2028 put demand (11th-percentile liquidity) hints at tail positioning.

October 28, 2026